Carleon Capital Partners LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 62.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,500 shares of the medical research company’s stock after selling 4,100 shares during the quarter. Carleon Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $519,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. increased its stake in Thermo Fisher Scientific by 2.0% in the first quarter. BlackRock Inc. now owns 24,582,453 shares of the medical research company’s stock valued at $5,075,294,000 after purchasing an additional 475,267 shares during the last quarter. Wells Fargo & Company MN increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock valued at $660,446,000 after purchasing an additional 9,820 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Thermo Fisher Scientific by 3.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,670,961 shares of the medical research company’s stock valued at $553,246,000 after purchasing an additional 82,255 shares during the last quarter. Brown Advisory Inc. increased its stake in Thermo Fisher Scientific by 2.4% in the first quarter. Brown Advisory Inc. now owns 2,144,864 shares of the medical research company’s stock valued at $442,830,000 after purchasing an additional 49,320 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Thermo Fisher Scientific by 1.7% in the second quarter. Janus Henderson Group PLC now owns 2,036,659 shares of the medical research company’s stock valued at $421,880,000 after purchasing an additional 34,401 shares during the last quarter. Institutional investors own 85.93% of the company’s stock.

Several research firms recently commented on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. Leerink Swann upped their target price on Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $230.00 to $233.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 26th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $239.08.

Shares of NYSE:TMO opened at $239.19 on Friday. The stock has a market cap of $95.83 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 1.73 and a beta of 1.13. The company has a quick ratio of 1.11, a current ratio of 1.58 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12 month low of $177.29 and a 12 month high of $240.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 25th. The medical research company reported $2.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.12. The company had revenue of $6.08 billion during the quarter, compared to analyst estimates of $5.90 billion. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The firm’s revenue was up 21.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.30 earnings per share. research analysts predict that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Shareholders of record on Monday, September 17th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $0.68 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $212.00, for a total transaction of $530,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 13th. The stock was sold at an average price of $217.71, for a total value of $10,885,500.00. Following the sale, the chief executive officer now owns 272,122 shares of the company’s stock, valued at $59,243,680.62. The disclosure for this sale can be found here. Insiders have sold 168,050 shares of company stock valued at $37,585,029 over the last 90 days. 0.49% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Understanding Analyst Recommendations

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.